Physician profile
Michael M Marvi
NPI 1205054129
$5,970.33
in general payments reported to CMS, 2019-2025
22 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,280 · 2020: $249 · 2021: $17.68 · 2022: $144 · 2023: $262 · 2024: $373 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,525.25 | 2019-2025 | |
| Portola Pharmaceuticals, LLC | $355.32 | 2019-2020 | |
| Boston Scientific Corporation | $316.10 | 2019 | |
| Amgen INC. | $284.33 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $213.71 | 2019-2025 | Nuplazid |
| Biogen, INC. | $174.73 | 2019-2024 | Skyclarys |
| Acorda Therapeutics, INC | $154.04 | 2019-2020 | |
| Grifols USA, LLC | $152.57 | 2023-2025 | Gamunex-C |
| Mdd US Operations, LLC | $150.91 | 2025 | Gocovri |
| Livanova USA, INC. | $142.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $117.82 | 2024 | Austedo Xr |
| Lilly USA, LLC | $64.03 | 2019-2025 | Kisunla |
| Allergan, INC. | $51.56 | 2020 | |
| Ge Healthcare | $50.07 | 2025 | |
| Supernus Pharmaceuticals, INC. | $36.34 | 2025 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.27 | 2025 | |
| Lundbeck LLC | $31.83 | 2023 | Vyepti |
| Banner Life Sciences, LLC | $31.60 | 2024 | |
| Revance Therapeutics, INC. | $23.36 | 2024 | Daxxify |
| Greenwich Biosciences, INC. | $22.18 | 2019 | |
| Abbott Laboratories | $21.58 | 2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $17.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.